Vascular endothelial growth factor and age-related macular degeneration: From basic science to therapy

Nature Medicine

Volumn 16, Issue 10, 2010, Pages 1107-1111

  Ferrara, Napoleone ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN; VERTEPORFIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANGIOGENESIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; HUMAN; NEOVASCULARIZATION (PATHOLOGY); NEUROENDOCRINOLOGY; NOTE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN FUNCTION; RETINA MACULA AGE RELATED DEGENERATION; RETINA VEIN OCCLUSION; VISUAL ACUITY; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); ENDOCRINOLOGY; HISTORY; MACULAR DEGENERATION; PHYSIOLOGY; RETINA NEOVASCULARIZATION; UNITED STATES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; ENDOCRINOLOGY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MACULAR DEGENERATION; RETINAL NEOVASCULARIZATION; UNITED STATES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77957764473     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1010-1107     Document Type: Note

References (56)

1. Ferrara, N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2, 795-803 (2002).
2. Ide, A.G., Baker, N.H. & Warren, S.L. Vascularization of the Brown Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. AJR Am. J. Roentgenol. 42, 891-899 (1939).
3. Algire, G.H., Chalkley, H.W., Legallais, F.Y. & Park, H.D. Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J. Natl. Cancer Inst. 6, 73-85 (1945).
4. Michaelson, I.C. The mode of development of the vascular system of the retina with some observations on its significance for certain retinal disorders. Trans. Ophthalmol. Soc. U. K. 68, 137-180 (1948).
5. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971).
6. Ferrara, N., Fujii, D.K., Goldsmith, P.C., Widdicombe, J.H. & Weiner, R.I. Transport epithelial characteristics of cultured bovine pituitary follicular cells. Am. J. Physiol. 252, E304-E312 (1987).
7. Ferrara, N. Vascular endothelial growth factor. Arterioscler. Thromb. Vasc. Biol. 29, 789-791 (2009).
8. Abraham, J.A. et al. Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. Science 233, 545-548 (1986).
9. Ferrara, N. & Henzel, W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161, 851-858 (1989).
10. Leung, D.W., Cachianes, G., Kuang, W.J., Goeddel, D.V. & Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306-1309 (1989).
11. Keck, P.J. et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246, 1309-1312 (1989).
12. Senger, D.R. et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983-985 (1983).
13. Houck, K.A., Leung, D.W., Rowland, A.M., Winer, J. & Ferrara, N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267, 26031-26037 (1992).
14. Park, J.E., Keller, G.-A. & Ferrara, N. The vascular endothelial growth factor isoforms (VEGF): differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell 4, 1317-1326 (1993).
15. Shibuya, M. et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family. Oncogene 5, 519-527 (1990).
16. de Vries, C. et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255, 989-991 (1992).
17. Terman, B.I. et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 187, 1579-1586 (1992).
18. Chung, A.S., Lee, J. & Ferrara, N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer 10, 505-514 (2010).
19. Kim, K.J. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362, 841-844 (1993).
20. Presta, L.G. et al. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593-4599 (1997).
21. Ferrara, N., Hillan, K.J., Gerber, H.P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391-400 (2004).
22. Davis-Smyth, T., Chen, H., Park, J., Presta, L.G. & Ferrara, N. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J. 15, 4919-4927 (1996).
23. Gerber, H.P. et al. VEGF is required for growth and survival in neonatal mice. Development 126, 1149-1159 (1999).
24. Gerber, H.P. et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med. 5, 623-628 (1999).
25. Ferrara, N. et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat. Med. 4, 336-340 (1998).
26. Ferrara, N. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439-442 (1996).
27. Carmeliet, P. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435-439 (1996).
28. Shweiki, D., Itin, A., Soffer, D. & Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843-845 (1992).
29. Aiello, L.P. et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331, 1480-1487 (1994).
30. Adamis, A.P. et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with prolif-erative diabetic retinopathy. Am. J. Ophthalmol. 118, 445-450 (1994).
31. Lopez, P.F., Sippy, B.D., Lambert, H.M., Thach, A.B. & Hinton, D.R. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neo-vascular membranes. Invest. Ophthalmol. Vis. Sci. 37, 855-868 (1996).
32. Kvanta, A., Algvere, P.V., Berglin, L. & Seregard, S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothe-lial growth factor. Invest. Ophthalmol. Vis. Sci. 37, 1929-1934 (1996).
33. Jager, R.D., Mieler, W.F. & Miller, J.W. Age-related macular degeneration. N. Engl. J. Med. 358, 2606-2617 (2008).
34. Aiello, L.P. et al. Suppression of retinal neovascular-ization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA 92, 10457-10461 (1995).
35. Adamis, A.P. et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch. Ophthalmol. 114, 66-71 (1996).
36. Campochiaro, P.A. & Hackett, S.F. Ocular neovascu-larization: a valuable model system. Oncogene 22, 6537-6548 (2003).
37. Ferris, F.L., III, Fine, S.L. & Hyman, L. Age-related macular degeneration and blindness due to neovascu-lar maculopathy. Arch. Ophthalmol. 102, 1640-1642 (1984).
38. Ferrara, N., Damico, L., Shams, N., Lowman, H. & Kim, R. Developmemt of Ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26, 859-870 (2006).
39. Raghavan, M. & Bjorkman, P.J. Fc receptors and their interactions with immunoglobulins. Annu. Rev. Cell Dev. Biol. 12, 181-220 (1996).
40. Chen, Y. et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J. Mol. Biol. 293, 865-881 (1999).
41. Krzystolik, M.G. et al. Prevention of experimental chor-oidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch. Ophthalmol. 120, 338-346 (2002).
42. Rosenfeld, P.J. et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1419-1431 (2006).
43. Brown, D.M. et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1432-1444 (2006).
44. Brown, D.M. et al. Ranibizumab versus verteporfin pho-todynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 116, 57-65 (2009).
45. Brown, D.M. et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117, 1124-1133 (2010).
46. Campochiaro, P.A. et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117, 1102-1112 (2010)
47. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovas-cularization in age-related macular degeneration with verteporfin. one-year results of 2 randomized clinical trials\TAP Report 1. Arch. Ophthalmol. 117, 1329-1345 (1999).
48. Gragoudas, E.S., Adamis, A.P., Cunningham, E.T. Jr., Feinsod, M. & Guyer, D.R. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351, 2805-2816 (2004).
49. Nagy, J.A. et al. Permeability properties of tumor surrogate blood vessels induced by VEGF-A. Lab. Invest. 86, 767-780 (2006).
50. Motiejunaite, R. & Kazlauskas, A. Pericytes and ocular diseases. Exp. Eye Res. 86, 171-177 (2008).
51. Yuan, F. et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci. USA 93, 14765-14770 (1996).
52. Benjamin, L.E., Golijanin, D., Itin, A., Pode, D. & Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103, 159-165 (1999).
53. Jain, R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005).
54. Bressler, N.M., Bressler, S.B. & Fine, S.L. Neovascular (exudative) age-related macular degeneration. in Retina vol. 2 (ed. Ryan, S.J.) 1075-1113 (Elsevier/Mosby, 2006), Macular Photocoagulation Study Group.
55. Macular Photocoagulation Study Group. Subfoveal neo-vascular lesions in age-related macular degeneration. Arch. Opthalmol. 109, 1242-1257 (1991).
56. Ferrara, N. Binding to the extracellular matrix and pro-teolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol. Biol. Cell 21, 687-690 (2010).